title: Neuromyotonia and myasthenia gravis in the absence of thymoma.
authors.forename: A
authors.initials: A
authors.lastname: Antelli
authors.forename: K
authors.initials: K
authors.lastname: Spengos
authors.forename: T
authors.initials: T
authors.lastname: Zambelis
authors.forename: D
authors.initials: D
authors.lastname: Pandis
authors.forename: G
authors.initials: G
authors.lastname: Tsivgoulis
authors.forename: V
authors.initials: V
authors.lastname: Zis
mesh_terms: D000368:Aged; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D006801:Humans; D020386:Isaacs Syndrome / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D051667:Kv1.6 Potassium Channel; D008297:Male; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D051637:Shaker Superfamily of Potassium Channels / Q000276:immunology; D013945:Thymoma; D013953:Thymus Neoplasms
chemical_list: D002800:Cholinesterase Inhibitors; C064389:KCNA6 protein, human; D051667:Kv1.6 Potassium Channel; D051637:Shaker Superfamily of Potassium Channels; D011729:Pyridostigmine Bromide